{
    "clinical_study": {
        "@rank": "136046", 
        "acronym": "TIARA", 
        "arm_group": {
            "arm_group_label": "Tacrolimus with Methotrexate", 
            "arm_group_type": "Experimental", 
            "description": "Subjects have tacrolimus per oral once daily with methotrexate for week 24. tacrolimus increased dosing regimen: 1 mg for 0~week4, 2mg for week4~week8,3mg for week8~week24"
        }, 
        "brief_summary": {
            "textblock": "The aims of this study are to assess the efficacy and safety of tacrolimus in patients with\n      active rheumatoid arthritis(RA). EULAR response at week 24 compared to baseline will be\n      evaluated to assess the efficacy of Tacrolimus."
        }, 
        "brief_title": "Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of\n      Tacrolimus(Tacrobell\u00ae)in patients with active rheumatoid arthritis(RA)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged \u226520years\n\n          -  Signed and dated informed consent document indicating that the patient\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test at\n             the screening visit. Except in the case of surgically sterile or amenorrhea for one\n             year.\n\n          -  Female patients must agree to use adequate contraception measures during the period\n             of therapy which should be continued for 4 weeks.\n\n          -  have RA and meet all of the following criteria; RA occurring \u2265 3months and less than\n             15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid\n             arthritis; Active RA patients with MTX and among them who has insufficiency response\n             to DMARDs as defined DAS28>3.2 in active RA patient. Insufficiency response is\n             defined despite MTX therapy for > 12 weeks, RA activity\u2265 more than moderate and\n             confirmable during 12 weeks, sequence of taking MTX >7.5mg/week for more than 6\n             weeks; ESR\u226528mm/h or CRP\u22651.0mg/dl; Tender Joint Counts must be more than 6 and\n             Swollen Joint Counts must be more than 3\n\n        Exclusion Criteria:\n\n          -  inflammatory joint diseases,systematic inflammatory disease\n\n          -  prosthesis and had an event of infected in it.\n\n          -  medical history of chronic infection, moderate infection or possibly to  life\n             threatening or signs and symptoms of serious infection\n\n          -  HBsAg positive and anti-HCV positive patient\n\n          -  uncontrollable blood sugar(HbA1C \u22658%) or required insulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746680", 
            "org_study_id": "m308RAP11M"
        }, 
        "intervention": {
            "arm_group_label": "Tacrolimus with Methotrexate", 
            "description": "TacroBell1\u00ae 1 mg for 0~week4, 2mg for week4~week8,3mg for week8~week24 with MTX \u226420mg/week", 
            "intervention_name": "Tacrolimus with Methotrexate", 
            "intervention_type": "Drug", 
            "other_name": "TacroBell\u00ae with MTX"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rheumatoid arthritis", 
            "RA", 
            "tacrolimus", 
            "DAS28", 
            "EULAR"
        ], 
        "lastchanged_date": "December 9, 2012", 
        "location": {
            "contact": {
                "email": "hsj718@khu.ac.kr", 
                "last_name": "Seung-Jae Hong, Ph.D", 
                "phone": "82-2-958-8199"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Kyung Hee University Hospital"
            }, 
            "investigator": {
                "last_name": "Seung -Jae Hong", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "hsj718@khu.ac.kr", 
            "last_name": "Seung Jae Hong, Ph.D", 
            "phone": "82-2-968-8199"
        }, 
        "overall_official": {
            "affiliation": "Kyung-Hee University Hospital", 
            "last_name": "Seung -Jae Hong, phD, Dr", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "all cause mortality", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}